NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models

Alessandra Zulian, Erika Rizzo, Marco Schiavone, Elena Palma, Francesca Tagliavini, Bert Blaauw, Luciano Merlini, Nadir M ario Maraldi, Patrizia Sabatelli, Paola Braghetta, Paolo Bonaldo, Francesco Argenton, Paolo Bernardi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are inherited muscle diseases due to mutations in the genes encoding the extracellular matrix protein collagen (Col) VI. Opening of the cyclosporin A-sensitive mitochondrial permeability transition pore (PTP) is a causative event in disease pathogenesis, and a potential target for therapy. Here, we have tested the effect of N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclophilin inhibitor, in a zebrafish model of ColVI myopathy obtained by deletion of the N-terminal region of the ColVI α1 triple helical domain, a common mutation of UCMD. Treatment with antisense morpholino sequences targeting col6a1 exon 9 at the 1-4 cell stage (within 1 h post fertilization, hpf) caused severe ultrastructural and motor abnormalities as assessed by electron and fluorescence microscopy, birefringence, spontaneous coiling events and touch-evoked responses measured at 24-48 hpf. Structural and functional abnormalities were largely prevented when NIM811--which proved significantly more effective than cyclosporin A--was administered at 21 hpf, while FK506 was ineffective. Beneficial effects of NIM811 were also detected (i) in primary muscle-derived cell cultures from UCMD and BM patients, where the typical mitochondrial alterations and depolarizing response to rotenone and oligomycin were significantly reduced; and (ii) in the Col6a1(-/-) myopathic mouse model, where apoptosis was prevented and muscle strength was increased. Since the PTP of zebrafish shares its key regulatory features with the mammalian pore, our results suggest that early treatment with NIM811 should be tested as a potential therapy for UCMD and BM.

Original languageEnglish
Pages (from-to)5353-5363
Number of pages11
JournalHuman Molecular Genetics
Volume23
Issue number20
DOIs
Publication statusPublished - Oct 15 2014

Fingerprint

Cyclophilins
Muscular Dystrophies
Immunosuppressive Agents
Collagen
Fertilization
Cyclosporine
Zebrafish
Birefringence
Oligomycins
Rotenone
Morpholinos
Mutation
Isoleucine
Extracellular Matrix Proteins
Touch
Muscle Strength
Tacrolimus
Muscular Diseases
Therapeutics
Fluorescence Microscopy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models. / Zulian, Alessandra; Rizzo, Erika; Schiavone, Marco; Palma, Elena; Tagliavini, Francesca; Blaauw, Bert; Merlini, Luciano; Maraldi, Nadir M ario; Sabatelli, Patrizia; Braghetta, Paola; Bonaldo, Paolo; Argenton, Francesco; Bernardi, Paolo.

In: Human Molecular Genetics, Vol. 23, No. 20, 15.10.2014, p. 5353-5363.

Research output: Contribution to journalArticle

Zulian, A, Rizzo, E, Schiavone, M, Palma, E, Tagliavini, F, Blaauw, B, Merlini, L, Maraldi, NMA, Sabatelli, P, Braghetta, P, Bonaldo, P, Argenton, F & Bernardi, P 2014, 'NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models', Human Molecular Genetics, vol. 23, no. 20, pp. 5353-5363. https://doi.org/10.1093/hmg/ddu254
Zulian, Alessandra ; Rizzo, Erika ; Schiavone, Marco ; Palma, Elena ; Tagliavini, Francesca ; Blaauw, Bert ; Merlini, Luciano ; Maraldi, Nadir M ario ; Sabatelli, Patrizia ; Braghetta, Paola ; Bonaldo, Paolo ; Argenton, Francesco ; Bernardi, Paolo. / NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models. In: Human Molecular Genetics. 2014 ; Vol. 23, No. 20. pp. 5353-5363.
@article{be006999ba9f411a9572186f45351d9d,
title = "NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models",
abstract = "Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are inherited muscle diseases due to mutations in the genes encoding the extracellular matrix protein collagen (Col) VI. Opening of the cyclosporin A-sensitive mitochondrial permeability transition pore (PTP) is a causative event in disease pathogenesis, and a potential target for therapy. Here, we have tested the effect of N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclophilin inhibitor, in a zebrafish model of ColVI myopathy obtained by deletion of the N-terminal region of the ColVI α1 triple helical domain, a common mutation of UCMD. Treatment with antisense morpholino sequences targeting col6a1 exon 9 at the 1-4 cell stage (within 1 h post fertilization, hpf) caused severe ultrastructural and motor abnormalities as assessed by electron and fluorescence microscopy, birefringence, spontaneous coiling events and touch-evoked responses measured at 24-48 hpf. Structural and functional abnormalities were largely prevented when NIM811--which proved significantly more effective than cyclosporin A--was administered at 21 hpf, while FK506 was ineffective. Beneficial effects of NIM811 were also detected (i) in primary muscle-derived cell cultures from UCMD and BM patients, where the typical mitochondrial alterations and depolarizing response to rotenone and oligomycin were significantly reduced; and (ii) in the Col6a1(-/-) myopathic mouse model, where apoptosis was prevented and muscle strength was increased. Since the PTP of zebrafish shares its key regulatory features with the mammalian pore, our results suggest that early treatment with NIM811 should be tested as a potential therapy for UCMD and BM.",
author = "Alessandra Zulian and Erika Rizzo and Marco Schiavone and Elena Palma and Francesca Tagliavini and Bert Blaauw and Luciano Merlini and Maraldi, {Nadir M ario} and Patrizia Sabatelli and Paola Braghetta and Paolo Bonaldo and Francesco Argenton and Paolo Bernardi",
year = "2014",
month = "10",
day = "15",
doi = "10.1093/hmg/ddu254",
language = "English",
volume = "23",
pages = "5353--5363",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "20",

}

TY - JOUR

T1 - NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models

AU - Zulian, Alessandra

AU - Rizzo, Erika

AU - Schiavone, Marco

AU - Palma, Elena

AU - Tagliavini, Francesca

AU - Blaauw, Bert

AU - Merlini, Luciano

AU - Maraldi, Nadir M ario

AU - Sabatelli, Patrizia

AU - Braghetta, Paola

AU - Bonaldo, Paolo

AU - Argenton, Francesco

AU - Bernardi, Paolo

PY - 2014/10/15

Y1 - 2014/10/15

N2 - Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are inherited muscle diseases due to mutations in the genes encoding the extracellular matrix protein collagen (Col) VI. Opening of the cyclosporin A-sensitive mitochondrial permeability transition pore (PTP) is a causative event in disease pathogenesis, and a potential target for therapy. Here, we have tested the effect of N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclophilin inhibitor, in a zebrafish model of ColVI myopathy obtained by deletion of the N-terminal region of the ColVI α1 triple helical domain, a common mutation of UCMD. Treatment with antisense morpholino sequences targeting col6a1 exon 9 at the 1-4 cell stage (within 1 h post fertilization, hpf) caused severe ultrastructural and motor abnormalities as assessed by electron and fluorescence microscopy, birefringence, spontaneous coiling events and touch-evoked responses measured at 24-48 hpf. Structural and functional abnormalities were largely prevented when NIM811--which proved significantly more effective than cyclosporin A--was administered at 21 hpf, while FK506 was ineffective. Beneficial effects of NIM811 were also detected (i) in primary muscle-derived cell cultures from UCMD and BM patients, where the typical mitochondrial alterations and depolarizing response to rotenone and oligomycin were significantly reduced; and (ii) in the Col6a1(-/-) myopathic mouse model, where apoptosis was prevented and muscle strength was increased. Since the PTP of zebrafish shares its key regulatory features with the mammalian pore, our results suggest that early treatment with NIM811 should be tested as a potential therapy for UCMD and BM.

AB - Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are inherited muscle diseases due to mutations in the genes encoding the extracellular matrix protein collagen (Col) VI. Opening of the cyclosporin A-sensitive mitochondrial permeability transition pore (PTP) is a causative event in disease pathogenesis, and a potential target for therapy. Here, we have tested the effect of N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclophilin inhibitor, in a zebrafish model of ColVI myopathy obtained by deletion of the N-terminal region of the ColVI α1 triple helical domain, a common mutation of UCMD. Treatment with antisense morpholino sequences targeting col6a1 exon 9 at the 1-4 cell stage (within 1 h post fertilization, hpf) caused severe ultrastructural and motor abnormalities as assessed by electron and fluorescence microscopy, birefringence, spontaneous coiling events and touch-evoked responses measured at 24-48 hpf. Structural and functional abnormalities were largely prevented when NIM811--which proved significantly more effective than cyclosporin A--was administered at 21 hpf, while FK506 was ineffective. Beneficial effects of NIM811 were also detected (i) in primary muscle-derived cell cultures from UCMD and BM patients, where the typical mitochondrial alterations and depolarizing response to rotenone and oligomycin were significantly reduced; and (ii) in the Col6a1(-/-) myopathic mouse model, where apoptosis was prevented and muscle strength was increased. Since the PTP of zebrafish shares its key regulatory features with the mammalian pore, our results suggest that early treatment with NIM811 should be tested as a potential therapy for UCMD and BM.

UR - http://www.scopus.com/inward/record.url?scp=84907922419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907922419&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddu254

DO - 10.1093/hmg/ddu254

M3 - Article

VL - 23

SP - 5353

EP - 5363

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 20

ER -